Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery
Status: Enrolling
Updated:  5/9/2013
Mayo Clinic
mi
from
Jacksonville, FL
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery
Status: Enrolling
Updated: 5/9/2013
Mayo Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery
Status: Enrolling
Updated:  5/9/2013
Florida Hospital Transplant Center
mi
from
Orlando, FL
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery
Status: Enrolling
Updated: 5/9/2013
Florida Hospital Transplant Center
mi
from
Orlando, FL
Click here to add this to my saved trials
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery
Status: Enrolling
Updated:  5/9/2013
Tampa General Hospital
mi
from
Tampa, FL
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery
Status: Enrolling
Updated: 5/9/2013
Tampa General Hospital
mi
from
Tampa, FL
Click here to add this to my saved trials
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery
Status: Enrolling
Updated:  5/9/2013
Loyola University Medical Center
mi
from
Proviso, IL
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery
Status: Enrolling
Updated: 5/9/2013
Loyola University Medical Center
mi
from
Proviso, IL
Click here to add this to my saved trials
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery
Status: Enrolling
Updated:  5/9/2013
Henry Ford Hospital
mi
from
Detroit, MI
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery
Status: Enrolling
Updated: 5/9/2013
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery
Status: Enrolling
Updated:  5/9/2013
Drexel University College of Medicine
mi
from
Philadelphia, PA
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery
Status: Enrolling
Updated: 5/9/2013
Drexel University College of Medicine
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery
Status: Enrolling
Updated:  5/9/2013
The University of Texas Health Science Center at Houston
mi
from
Houston, TX
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery
Status: Enrolling
Updated: 5/9/2013
The University of Texas Health Science Center at Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery
Status: Enrolling
Updated:  5/9/2013
Brooke Army Medical Center
mi
from
Fort Sam Houston, TX
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery
Status: Enrolling
Updated: 5/9/2013
Brooke Army Medical Center
mi
from
Fort Sam Houston, TX
Click here to add this to my saved trials
Feasibility Study of Dynasplint to Prevent Trismus in Head and Neck Cancer
A Feasibility Study to Evaluate Use of the Jaw Dynasplint System to Prevent Trismus in Patients With Head and Neck Cancer Receiving Primary or Adjuvant Radiation-Based Therapy
Status: Enrolling
Updated:  5/10/2013
Vanderbilt University
mi
from
Nashville, TN
Feasibility Study of Dynasplint to Prevent Trismus in Head and Neck Cancer
A Feasibility Study to Evaluate Use of the Jaw Dynasplint System to Prevent Trismus in Patients With Head and Neck Cancer Receiving Primary or Adjuvant Radiation-Based Therapy
Status: Enrolling
Updated: 5/10/2013
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer
Randomized Phase II Study of Cabazitaxel Versus Topotecan in Small Cell Lung Cancer Patients With Progressive Disease During or After a First Line Platinum Based Chemotherapy
Status: Enrolling
Updated:  5/15/2013
Clinical Research Facility
mi
from
Muscle Shoals, AL
Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer
Randomized Phase II Study of Cabazitaxel Versus Topotecan in Small Cell Lung Cancer Patients With Progressive Disease During or After a First Line Platinum Based Chemotherapy
Status: Enrolling
Updated: 5/15/2013
Clinical Research Facility
mi
from
Muscle Shoals, AL
Click here to add this to my saved trials
Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer
Randomized Phase II Study of Cabazitaxel Versus Topotecan in Small Cell Lung Cancer Patients With Progressive Disease During or After a First Line Platinum Based Chemotherapy
Status: Enrolling
Updated:  5/15/2013
Clinical Research Facility
mi
from
Omaha, NE
Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer
Randomized Phase II Study of Cabazitaxel Versus Topotecan in Small Cell Lung Cancer Patients With Progressive Disease During or After a First Line Platinum Based Chemotherapy
Status: Enrolling
Updated: 5/15/2013
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer
Randomized Phase II Study of Cabazitaxel Versus Topotecan in Small Cell Lung Cancer Patients With Progressive Disease During or After a First Line Platinum Based Chemotherapy
Status: Enrolling
Updated:  5/15/2013
Clinical Research Facility
mi
from
Lebanon, NH
Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer
Randomized Phase II Study of Cabazitaxel Versus Topotecan in Small Cell Lung Cancer Patients With Progressive Disease During or After a First Line Platinum Based Chemotherapy
Status: Enrolling
Updated: 5/15/2013
Clinical Research Facility
mi
from
Lebanon, NH
Click here to add this to my saved trials
Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer
Randomized Phase II Study of Cabazitaxel Versus Topotecan in Small Cell Lung Cancer Patients With Progressive Disease During or After a First Line Platinum Based Chemotherapy
Status: Enrolling
Updated:  5/15/2013
Clinical Research Facility
mi
from
Middletown, OH
Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer
Randomized Phase II Study of Cabazitaxel Versus Topotecan in Small Cell Lung Cancer Patients With Progressive Disease During or After a First Line Platinum Based Chemotherapy
Status: Enrolling
Updated: 5/15/2013
Clinical Research Facility
mi
from
Middletown, OH
Click here to add this to my saved trials
Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer
Randomized Phase II Study of Cabazitaxel Versus Topotecan in Small Cell Lung Cancer Patients With Progressive Disease During or After a First Line Platinum Based Chemotherapy
Status: Enrolling
Updated:  5/15/2013
Clinical Research Facility
mi
from
Philadelphia, PA
Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer
Randomized Phase II Study of Cabazitaxel Versus Topotecan in Small Cell Lung Cancer Patients With Progressive Disease During or After a First Line Platinum Based Chemotherapy
Status: Enrolling
Updated: 5/15/2013
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer
Randomized Phase II Study of Cabazitaxel Versus Topotecan in Small Cell Lung Cancer Patients With Progressive Disease During or After a First Line Platinum Based Chemotherapy
Status: Enrolling
Updated:  5/15/2013
Clinical Research Facility
mi
from
Philadelphia, PA
Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer
Randomized Phase II Study of Cabazitaxel Versus Topotecan in Small Cell Lung Cancer Patients With Progressive Disease During or After a First Line Platinum Based Chemotherapy
Status: Enrolling
Updated: 5/15/2013
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer
Randomized Phase II Study of Cabazitaxel Versus Topotecan in Small Cell Lung Cancer Patients With Progressive Disease During or After a First Line Platinum Based Chemotherapy
Status: Enrolling
Updated:  5/15/2013
Clinical Research Facility
mi
from
Salt Lake City, UT
Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer
Randomized Phase II Study of Cabazitaxel Versus Topotecan in Small Cell Lung Cancer Patients With Progressive Disease During or After a First Line Platinum Based Chemotherapy
Status: Enrolling
Updated: 5/15/2013
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  5/16/2013
Northwest Alabama Cancer Center, PC
mi
from
Muscle Shoals, AL
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 5/16/2013
Northwest Alabama Cancer Center, PC
mi
from
Muscle Shoals, AL
Click here to add this to my saved trials
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  5/16/2013
Genesis Cancer Center
mi
from
Hot Springs, AR
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 5/16/2013
Genesis Cancer Center
mi
from
Hot Springs, AR
Click here to add this to my saved trials
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  5/16/2013
Providence Health System: Roy and Patricia Disney Family Cancer Center
mi
from
Burbank, CA
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 5/16/2013
Providence Health System: Roy and Patricia Disney Family Cancer Center
mi
from
Burbank, CA
Click here to add this to my saved trials
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  5/16/2013
Compassionate Cancer Care Medical Group, Inc.
mi
from
Corona, CA
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 5/16/2013
Compassionate Cancer Care Medical Group, Inc.
mi
from
Corona, CA
Click here to add this to my saved trials
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  5/16/2013
City of Hope
mi
from
Upper San Gabriel Valley, CA
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 5/16/2013
City of Hope
mi
from
Upper San Gabriel Valley, CA
Click here to add this to my saved trials
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  5/16/2013
Robert A. Moss, M.D. FACP, Inc.
mi
from
Fountain Valley, CA
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 5/16/2013
Robert A. Moss, M.D. FACP, Inc.
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  5/16/2013
California Cancer Associates for Research and Excellence
mi
from
Encinitas, CA
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 5/16/2013
California Cancer Associates for Research and Excellence
mi
from
Encinitas, CA
Click here to add this to my saved trials
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  5/16/2013
Marin Specialty Care
mi
from
Greenbrae, CA
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 5/16/2013
Marin Specialty Care
mi
from
Greenbrae, CA
Click here to add this to my saved trials
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  5/16/2013
UCLA Med-Hematology & Oncology
mi
from
Los Angeles, CA
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 5/16/2013
UCLA Med-Hematology & Oncology
mi
from
Los Angeles, CA
Click here to add this to my saved trials
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  5/16/2013
Good Samaritan Hospital
mi
from
San Jose, CA
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 5/16/2013
Good Samaritan Hospital
mi
from
San Jose, CA
Click here to add this to my saved trials
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  5/16/2013
American Institute of Research
mi
from
Whittier, CA
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 5/16/2013
American Institute of Research
mi
from
Whittier, CA
Click here to add this to my saved trials
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  5/16/2013
Centura Health Research Center
mi
from
Denver, CO
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 5/16/2013
Centura Health Research Center
mi
from
Denver, CO
Click here to add this to my saved trials
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  5/16/2013
Western Oncology & Hematology
mi
from
Golden, CO
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 5/16/2013
Western Oncology & Hematology
mi
from
Golden, CO
Click here to add this to my saved trials
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  5/16/2013
Cancer Care Centers of Florida: Brooksville
mi
from
Brooksville, FL
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 5/16/2013
Cancer Care Centers of Florida: Brooksville
mi
from
Brooksville, FL
Click here to add this to my saved trials
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  5/16/2013
Broward Oncology Associates
mi
from
Fort Lauderdale, FL
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 5/16/2013
Broward Oncology Associates
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  5/16/2013
University of Florida Shands Cancer Center
mi
from
Gainesville, FL
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 5/16/2013
University of Florida Shands Cancer Center
mi
from
Gainesville, FL
Click here to add this to my saved trials
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  5/16/2013
Cancer Specialists of North Florida
mi
from
Jacksonville, FL
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 5/16/2013
Cancer Specialists of North Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  5/16/2013
Advanced Pharma CR, LLC
mi
from
Miami, FL
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 5/16/2013
Advanced Pharma CR, LLC
mi
from
Miami, FL
Click here to add this to my saved trials
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  5/16/2013
Cancer Care Centers Of Florida
mi
from
Brooksville, FL
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 5/16/2013
Cancer Care Centers Of Florida
mi
from
Brooksville, FL
Click here to add this to my saved trials
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  5/16/2013
Ocala Cancer Institute
mi
from
Ocala, FL
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 5/16/2013
Ocala Cancer Institute
mi
from
Ocala, FL
Click here to add this to my saved trials
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  5/16/2013
Cancer Care Centers of Brevard
mi
from
Melbourne, FL
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 5/16/2013
Cancer Care Centers of Brevard
mi
from
Melbourne, FL
Click here to add this to my saved trials
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  5/16/2013
Northeast Georgia Cancer Care
mi
from
Athens, GA
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 5/16/2013
Northeast Georgia Cancer Care
mi
from
Athens, GA
Click here to add this to my saved trials
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  5/16/2013
Dublin Hematology and Oncology Care
mi
from
Dublin, GA
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 5/16/2013
Dublin Hematology and Oncology Care
mi
from
Dublin, GA
Click here to add this to my saved trials
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  5/16/2013
Kootenai Cancer Center
mi
from
Coeur d'Alene, ID
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 5/16/2013
Kootenai Cancer Center
mi
from
Coeur d'Alene, ID
Click here to add this to my saved trials
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  5/16/2013
Northwestern University - Robert H Lurie Comprehensive Cancer Center
mi
from
Chicago, IL
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 5/16/2013
Northwestern University - Robert H Lurie Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  5/16/2013
Medical and Surgical Specialists, LLC
mi
from
Galesburg, IL
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 5/16/2013
Medical and Surgical Specialists, LLC
mi
from
Galesburg, IL
Click here to add this to my saved trials
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  5/16/2013
Edward H. Kaplan, M.D. & Associates
mi
from
Skokie, IL
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 5/16/2013
Edward H. Kaplan, M.D. & Associates
mi
from
Skokie, IL
Click here to add this to my saved trials
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  5/16/2013
Deaconess Clinic, Inc.
mi
from
Evansville, IN
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 5/16/2013
Deaconess Clinic, Inc.
mi
from
Evansville, IN
Click here to add this to my saved trials
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  5/16/2013
Fort Wayne Oncology & Hematology, Inc
mi
from
Fort Wayne, IN
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 5/16/2013
Fort Wayne Oncology & Hematology, Inc
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  5/16/2013
IU Health Goshen
mi
from
Goshen, IN
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 5/16/2013
IU Health Goshen
mi
from
Goshen, IN
Click here to add this to my saved trials
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  5/16/2013
IU Health Central Indiana Cancer Centers
mi
from
Indianapolis, IN
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 5/16/2013
IU Health Central Indiana Cancer Centers
mi
from
Indianapolis, IN
Click here to add this to my saved trials
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  5/16/2013
Community Regional Cancer Center
mi
from
Indianapolis, IN
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 5/16/2013
Community Regional Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  5/16/2013
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 5/16/2013
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  5/16/2013
Horizon Oncology Research
mi
from
Lafayette, IN
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 5/16/2013
Horizon Oncology Research
mi
from
Lafayette, IN
Click here to add this to my saved trials